We examined whether vascular endothelial growth factor (VEGF) polymorphisms (C-2578A, G-1154A and G-634C) are associated with hypertension, response to antihypertensive therapy and nitric oxide (NO) formation. Substudy 1 compared the distribution of VEGF genotypes and haplotypes in 178 patients with arterial hypertension (100 whites and 78 blacks) and 186 healthy controls (115 whites and 71 blacks). Substudy 2 compared the distribution of VEGF markers in 82 patients with controlled hypertension, 89 patients with resistant hypertension and 101 normotensive (NT) patients. In substudy 3, plasma nitrite/nitrate (NOx) levels were determined (chemiluminescence assay) in 64 NT subjects and 48 hypertensive (HTN) subjects, and the distribution of VEGF markers was compared in subjects having low NOx with subjects having high NOx. Although the substudy 1 showed no differences in genotypes or allele distributions for the three VEGF polymorphisms between NT and HTN subjects, the 'C-A-G' haplotype was more common in white NT subjects than in the white HTN subjects, and the 'C-A-C' haplotype was more frequent in black and white HTN subjects than in black and white NT subjects. The substudy 2 showed similar results, with no differences between responsive and resistant HTN subjects. The substudy 3 showed that the 'C-A-G' haplotype, which had a protective effect against hypertension, was significantly more common in subjects with higher NOx concentrations than in subjects with lower NOx concentrations. VEGF haplotypes are associated with hypertension, and the haplotype associated with normotension was more common in subjects with increased NO formation, possibly offering a mechanistic clue for our findings.
INTRODUCTION
Vascular endothelial growth factor (VEGF) is a glycoprotein expressed mostly by endothelial cells and has many biological roles, including proliferation, migration and survival of endothelial cells. 1, 2 Because VEGF causes vasodilatation and is a major regulator of angiogenesis and vascular permeability, 3 --5 genetic polymorphisms in the VEGF gene have been suggested as a contributing factor for the development of disease conditions. 6 --9 Taking into consideration that VEGF is a vasodilator and stimulates endogenous nitric oxide (NO) production, 4,10 --12 it is reasonable to suggest that it affects arterial blood pressure (BP) regulation. Lower VEGF and nitrite/nitrate (products of NO oxidation) levels were described in hypertensive (HTN) patients compared with healthy subjects, and these biomarkers correlated positively in healthy subjects, but not in HTN subjects. 13 Indeed, NO is a major physiological vasodilator, 14 and impaired NO bioavailability apparently contributes to clinical hypertension. 15 Therefore, it is possible that genetic polymorphisms in the VEGF gene contribute to cardiovascular disease susceptibility, in particular to hypertension. Although we have previously shown that combinations of VEGF genetic variants (VEGF haplotypes) affect the susceptibility to preeclampsia, 6 no previous study has examined whether VEGF polymorphisms affect the susceptibility to hypertension. In the present study, we studied the association of three functional VEGF polymorphisms (C-2578A, G-1154A and G-634C, located in the promoter region of VEGF gene) with hypertension.
The main aim of the current study was to examine whether VEGF gene polymorphisms are associated with hypertension. To test this hypothesis, and to examine possible clinical implications of VEGF polymorphisms, we carried out three substudies. The substudy 1 aimed at comparing the distribution of genetic variants (genotypes and haplotypes) of the three abovementioned VEGF polymorphisms in HTN subjects with those found in control, normotensive (NT) subjects. This comparison was carried separately in black and white subjects because interethnic differences exist in the distribution of VEGF variants. 16 The substudy 2 aimed at comparing the distribution of VEGF genetic variants in HTN patients, who are resistant to conventional antihypertensive therapy (resistant hypertensive (RHTN)), with those found in controlled HTN subjects and with NT healthy controls. This substudy could implicate VEGF polymorphisms in the pathophysiological mechanisms, leading to resistant hypertension. In the substudy 3, we measured the plasma nitrite þ nitrate levels (which may reflect endogenous NO formation) to investigate whether VEGF polymorphisms affect NO bioavailability in HTN and NT subjects.
MATERIALS AND METHODS

Study population
at the Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, and each subject provided written informed consent.
Substudy 1
A total of 178 patients with arterial hypertension (HTN group; 100 whites and 78 blacks) were recruited from our hospital hypertension clinic (at the Faculty of Medicine of Ribeirao Preto, University of Sao Paulo) and 186 healthy controls (NT group; 115 whites and 71 blacks) were recruited from general public. All the subjects provided a complete health history and underwent a physical examination and laboratory analysis. BP measurement was taken three times from all volunteers, with subjects in the seated position and with the use of an automatic BP device, according to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. 17 The individuals were considered HTN if their systolic or diastolic BP was 4140 or 490 mm Hg, respectively, or were on antihypertensive therapy. Patients with secondary forms of hypertension, cardiac or cerebral ischemic vascular diseases, impaired renal function, or other diseases were excluded from the study.
Substudy 2
We recruited from our hospital outpatient clinic (at the Faculty of Medical Sciences, State University of Campinas) 82 patients with arterial hypertension who were well controlled (HTN) and 89 HTN patients who were resistant to conventional antihypertensive therapy (RHTN). All RHTN patients had uncontrolled office and ambulatory BP (systolic BP 4140 mm Hg and diastolic BP 490 mm Hg), in spite of the institution of an optimal regimen defined as one including three or more antihypertensive drugs at full doses, including a diuretic, after excluding potential identifiable hypertension as recommended by the American Heart Association. 17 Moreover, to avoid bias in the assessment of resistance to antihypertensive therapy, we have included in the present study only patients prospectively followed for at least 2 years. Normal healthy volunteers (NT, n ¼ 101) consisted of randomly selected individuals recruited from the local population, and genetically unrelated to the patients included in the other study groups.
Substudy 3
Two groups of subjects were studied: 64 NT volunteers recruited from general public and 48 patients with arterial hypertension recruited from our hospital hypertension clinic (at the Faculty of Medicine of Ribeirao Preto, University of Sao Paulo), as described above. Venous blood samples were drawn from these subjects to measure plasma nitrite/nitrate (NOx) concentrations as described below. To assess a possible genetic contribution of VEGF polymorphisms to NO formation, we compared the distribution of genotypes, alleles and the estimated haplotypes frequencies in subjects with the 50% lowest NOx concentrations (low (L) group) with those found in subjects with the 50% highest NOx (high (H) group) concentrations in both NT and HTN subjects.
Genotyping
Genomic DNA was extracted from the cellular component of 1 ml of venous blood samples by a salting-out method and stored at À20 1C until analyzed. Three clinically relevant polymorphisms in the promoter region of the VEGF gene were studied: C-2578A (rs699947), G-1154A (rs1570360) and G-634C (rs2010963). Genotypes were determined by TaqMan Allele Discrimination assay (Applied Biosystems, Foster City, CA, USA), using probes and primers designed by Applied Biosystems (assay ID: C_8311602_10/-2578; C_1647379_10/-1154; and C_8311614_10/-634). TaqMan PCR was performed in a total volume of 12 ml (3 ng of dried DNA, 1 Â TaqMan master mix, 900 nM of each primer and 200 nM of each probe) placed in 96-well PCR plates. Fluorescence from PCR amplification was detected using Chromo 4 Detector (Bio-Rad Laboratories, Hercules, CA, USA) and analyzed with manufacturer's software. The PCR conditions were as follows: one step of 10 min at 95 1C, followed by 40 cycles of DNA denaturation at 92 1C for 15 s and annealing/extension at 60 1C for 1 min.
Measurement of plasma NOx concentrations
NO is rapidly oxidized to more stable metabolites such as NOx, thus making it difficult to measure NO production. However, the circulating NOx levels may reflect endogenous NO synthesis. Because the plasma NOx levels may be affected by food/water content, blood samples were collected from all subjects after an overnight fasting (412 h), thus decreasing the likelihood that NOx measurements would be affected by the diet. 18 Venous blood samples were collected from subjects enrolled in the substudy 3 after overnight fasting (412 h) into tubes containing EDTA and immediately centrifuged at 1000 g for 4 min. Plasma aliquots were immediately removed and stored at À70 1C until analyzed in duplicate for their nitrites þ nitrates content using an ozone-based chemiluminescence assay as previously described. 18, 19 Statistical analyses
The clinical characteristics were compared between groups by Student unpaired t-test or one-way analysis of variance, followed by Bonferroni's test or w 2 -tests. The distribution of genotypes for each polymorphism was assessed for deviation from the Hardy --Weinberg equilibrium, and differences in genotype frequency and in allele frequency between groups were assessed using w 2 -tests. A value of Po0.05 was considered statistically significant.
The estimating haplotype software program (http://linkage.rockefeller. edu/ott/eh.htm; accessed on 14 March 2011) was used to estimate the haplotype frequencies in each group. 20, 21 In addition, to identify which specific haplotypes were associated with susceptibility to hypertension or resistance to antihypertensive therapy, differences in haplotype frequency were further tested using a contingency table, and a value of Po0.00625 (0.05 per number of haplotypes) was considered significant to correct for the number of comparisons made. To further confirm haplotype frequency estimates, we have also used the Haplo.stats software (version 1.4.4, http://cran.r-project.org/web/packages/haplo.stats/index.html). The function haplo.em computes maximum likelihood estimates of haplotype probabilities using the progressive insertion algorithm, which progressively inserts batches of loci into haplotypes of growing lengths. 20 Table 1 summarizes the characteristics of the 364 subjects enrolled in the substudy 1. NT and HTN subjects were similar with respect to their clinical characteristics, except for typical differences in systolic and diastolic BP (Table 1) . Table 2 shows the results of the single-locus analysis for the substudy 1. Because there are interethnic differences in the distribution of VEGF gene variants, 16 we analyzed the results according to ethnicity. In both ethnic groups (blacks and whites), we found no significant differences in genotypes or alleles distributions for the three VEGF polymorphisms when NT and HTN subjects were compared (Table 2 ; all P40.05). Interestingly, even though negative results were found when genotype or allele frequencies distributions were compared, we found significant differences in the overall distribution of VEGF haplotype frequencies in NT compared to HTN white subjects (P ¼ 0.005; Table 3 ). In particular, the H3 haplotype (C-A-G) was more commonly found in white NT than in the white HTN subjects (14/ 230 versus 0/200; P ¼ 0.0001; Table 3 ), thus suggesting a protective effect for this haplotype against hypertension susceptibility in white subjects. Conversely, we found no significant differences in overall haplotypes frequencies when black NT subjects were compared with black HTN subjects. However, although the H4 was more frequent in black and white HTN subjects than in black and white NT subjects (5/156 and 5/200, respectively, versus 0/142 and 0/230, respectively; P ¼ 0.034 and P ¼ 0.017, respectively; Table 3 ), these findings did not resist to the correction for multiple comparisons because they did not remain significant after Bonferroni's correction (corrected P c o0.00625). Table 1 summarizes the characteristics of the 272 subjects enrolled in the substydy 2. The three groups of subjects were similar, except that HTN and RHTN subjects had higher systolic and diastolic BP than NT controls (Table 1) .
RESULTS
Substudy 1
Although we found that genotypes and alleles distributions for the three polymorphisms were not significantly different when the three groups of subjects were compared (Table 4 ; all P40.05), significant differences in the overall distribution of VEGF haplotypes were found when the HTN and RHTN groups were compared with the NT group (P ¼ 0.002 and P ¼ 0.003, respectively; Table 4 ). Specifically, the H4 haplotype (C-A-C) was found in the HTN and RHTN groups, but not in the NT group (8/164 and 7/ 178 versus 0/202, respectively; P ¼ 0.0015 and P ¼ 0.0046, respectively; Table 5 ). Interestingly, the H3 haplotype was apparently more frequent in the NT group than in the HTN and RHTN groups (8/202 versus 0/164 and 0/178, respectively; P ¼ 0.011 and P ¼ 0.008, respectively, to RHTN), thus suggesting a protective effect of this haplotype against hypertension, as suggested by the substudy 1. However, these H3 haplotype results did not remain significant after Bonferroni's correction (P c o0.00625). Finally, the distribution of VEGF haplotypes was not significantly different when the HTN group was compared with the RHTN group (P40.05; Table 5 ), thus suggesting that VEGF haplotypes are not associated with resistance to antihypertensive therapy. Table 6 summarizes the characteristics of the 112 subjects enrolled in the substudy 3. The main objective of this substudy was to determine whether there is any difference in the distribution of VEGF genotypes or haplotypes when subjects in the low-plasma NOx levels are compared with those found in the high-plasma NOx levels. We found no significant differences in the clinical features between subjects in the L and those in the H groups (except for NOx levels; Table 6 ).
Substudy 3
We found that the GG genotype for the G-634T polymorphism is more commonly found in the H group than in the L group of NT subjects (65% versus 37%; P ¼ 0.0005; Figure 1a) . Correspondingly, the GC and CC genotypes for this polymorphism were more common in the L group than in the H group of NT subjects (43% and 20% versus 26% and 10%, respectively; both Po0.05; Figure 1a ), although this difference may not resist to correction for multiple comparisons. No other genotype effects were found in both NT and HTN subjects (Figures 1a and b) .
Although we found no differences in the haplotype distributions when the L and H groups of NT subjects were compared (Figure 1c ), significant differences were found between the L and H groups of HTN subjects (Po0.05; Figure 1d) . Specifically, the H3 Abbreviations: HTN, hypertensive; NT, normotensive. The distribution of genotypes for the three polymorphisms studied here showed no deviation from Hardy --Weinberg equilibrium. P, probability value for NT versus HTN.
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haplotype (C-A-G), which had a protective effect against hypertension in the substudy 1, was significantly more common in the H group than in the L group (9% versus 0%; Po0.006; Figure 1d ).
DISCUSSION
This study was the first to assess a possible association between hypertension and VEGF haplotypes. Our results suggest lack of significant association between hypertension and individual VEGF polymorphisms. Conversely, we found important differences when genetic markers were combined within haplotypes, thus supporting the idea that multiple genetic markers within a haplotype may interact and affect the susceptibility to disease conditions. 21, 22 In the substudy 1, there are clear interethnic differences in the distribution of VEGF genetic variants, as previously shown. 16 In fact, our results in blacks and whites are very similar to those previously reported in these two ethnic groups. 16 These results confirm the relevance of considering population stratification due to ethnic diversity in association studies, which may cause unbalanced distribution of genetic variants and decrease the power of association studies. 23 In the present study, ethnicity has been defined with basis on self-reporting. Although there is concern about this criterion to define ethnicity, self-reporting has been regarded as one of the best criteria. 24 Interestingly, we found no association between VEGF genotypes/alleles and hypertension, both in black and in white subjects. Our findings are in line with those reported in recent study evaluating the association between several VEGF polymorphisms and hypertension in 62 NT and 62 HTN individuals. 25 Although the authors found significant association of two VEGF polymorphisms (G-152A and G-116A) and hypertension, they found no significant association between the C-1154A and G-634C polymorphisms, thus supporting our negative findings with respect to individual polymorphisms. However, this previous study has not examined whether VEGF haplotypes are associated with hypertension.
We found significant differences in the distribution of VEGF haplotypes when white HTN subjects were compared with white NT subjects (P ¼ 0.005). Interestingly, the H3 haplotype (C-A-G) was more common in white NT subjects than in white HTN subjects, thus suggesting a protective role for this haplotype against hypertension. In contrast, we found a trend for the H4 haplotype (C --A-C) to be more frequent in white and black HTN patients than in white and black NT subjects (P ¼ 0.017 and P ¼ 0.034, respectively), thus suggesting that this haplotype may affect the susceptibility to hypertension independent of ethnicity. Indeed, if genetic markers are really determinants of disease susceptibility, they should probably be consistently found in association with disease conditions, independent of ethnicity or other associated conditions, as previously reported. 21 It should be noted that the association involving the H3 haplotype in white subjects was not found in black subjects, probably as a consequence of the very low frequency of the H3 haplotype in black subjects. 16 In fact, the H3 haplotype frequency in blacks was previously reported as zero, 16 and although we found this haplotype in five black HTN subjects, we found it in no black NT. These findings align with the suggestion that genetic markers associated with hypertension may be independent of ethnicity.
The substudy 2 was carried with patients and controls from another population, and our overall results confirm those found in the substudy 1. The H3 haplotype was more frequent in NT than in HTN subjects, and the H4 haplotype was significantly more common in the HTN and RHTN groups than in the NT group (both Table 3 . Estimated haplotype distribution in black and white subjects in the substudy 1 G  51  61  NS  46  38  NS  H2  C  G  C  43  48  NS  65  65  NS  H3  C  A  G  2  0  NS  14  0  0.0001  H4  C  A  C  0  5  NS  0  5  NS  H5  A  G  G  23  18  NS  40  30  NS  H6  A  G  C  1  2  NS  0  0  NS  H7  A  A  G  21  22  NS  63  60  NS  H8 A
Abbreviations: HTN, hypertensive; NS, nonsignificant; NT, normotensive. P c o0.00625 (or 0.05/8); n ¼ number of haplotypes. Abbreviations: HTN, hypertensive; NT, normotensive; RHTN, resistant hypertensive. The distribution of genotypes for the three polymorphisms studied here showed no deviation from Hardy --Weinberg equilibrium. P a , P-value for HTN versus NT; P b , P value for RHTN versus NT.
VEGF polymorphisms and hypertension VC Sandrim et al Table 5 . Estimated haplotypes distribution in NT, HTN and RHTN groups (substudy 2) G  59  42  55  NS  NS  H2  C  G  C  53  56  48  NS  NS  H3  C  A  G  8  0  0  NS  NS  H4  C  A  C  0 Po0.0065), thus further supporting the suggestion that these haplotypes affect the susceptibility to hypertension. Moreover, we examined whether VEGF haplotypes are associated with resistance to conventional antihypertensive therapy. The lack of significant differences in the VEGF genotypes and haplotypes distributions in the HTN group compared with the RHTN group suggests that there is no influence of the VEGF gene variants on the responsiveness to antihypertensive therapy. Resistance to antihypertensive therapy is usually accompanied by extensive target organ damage, which may itself reduce the clinical response to antihypertensive drugs. 26 Indeed, VEGF may have a role in the pathophysiology of hypertension-induced damage in target organs, as suggested by some authors. 27 --29 VEGF gene expression is regulated by complex mechanisms involving the transcriptional and translational levels. 30, 31 The three polymorphisms studied here were shown to modify VEGF gene promoter activity, and therefore affect the circulating VEGF levels in vivo.
8, 32 Although we have not attempted to demonstrate the mechanisms through which VEGF genetic variations can affect the susceptibility to hypertension in the present study, our results suggest that the haplotype analysis may be more important than the analysis of single polymorphisms.
VEGF may affect the arterial BP by promoting NO formation as a result of AKT/protein B kinase activation, which promotes endothelial nitric oxide synthase phosphorylation. 4,10 --12,33 Interestingly, anti-VEGF therapy induces hypertension 34 --37 as a side effect, and this is mediated by inhibition of NO production. 38 Therefore, in the substudy 3, we examined whether VEGF genotypes or haplotypes affect the circulating NOx levels in HTN and NT subjects. Indeed, NOx are stable end products of NO metabolism, and most circulating NOx in fasted subjects derives from NOS activity. 39 Although essential hypertension has been associated with decreased or unaltered NO bioavailability, 13,40 --42 we found increased plasma NOx in HTN compared with NT subjects (91 ± 58 versus 44 ± 19 mmol/l, respectively; Po0.05), as previously shown, 19 and our results may reflect a compensatory increase in NO synthesis secondary to increased shear stress and endothelial nitric oxide synthase activity in hypertension 43 or the effects of antihypertensive or other drugs used by patients, which may affect NOx concentrations. 42, 44, 45 Interestingly, although no previous study has analyzed the effects of VEGF polymorphism on NOx levels, we found higher NOx levels apparently in association with the GG genotype for the G-634C polymorphism in NT subjects, whereas carriers of the C allele for this polymorphism apparently have lower NOx levels. The other VEGF polymorphisms had no effects on NOx levels, both in patients and NT subjects. Interestingly, the haplotype analysis showed that the 'protective' H3 haplotype (more frequent in NT than in HTN subjects) was associated with high NOx levels. These findings are consistent with the suggestion that the haplotype H3 may promote NO formation in vivo, thus contributing to protection against hypertension. It should be noted that the findings for the substudy 3 may be limited by the relatively small number of subjects enrolled in this substudy. Although we found no significant differences in NOx levels when white and black subjects were compared (P40.05), neither when males and females were compared (P40.05), the percentage of men differs between HTN and NT subjects (Po0.05). A more detailed, larger study should be carried out to confirm these preliminary findings.
In addition, further studies should assess the circulating nitrites concentrations, which probably reflect better endogenous NO formation, 46, 47 although NOx have usually been used with this objective.
In conclusion, our findings show that specific VEGF haplotypes are associated with normotension (C --A-G) and hypertension (C-A-C), thus supporting the idea that VEGF polymorphisms may affect the susceptibility to hypertension when combinations of VEGF genetic markers are taken into consideration. Moreover, the haplotype associated with normotension was found in association with increased NO formation, possibly offering a mechanistic clue for the association between the 'C-A-G' haplotype and 'protection' against hypertension.
What is known about this topic
Vascular endothelial growth factor (VEGF) causes vasodilatation and is a major regulator of angiogenesis and vascular permeability. Although VEGF gene polymorphisms contribute to disease susceptibility, no previous study has examined whether functional VEGF polymorphisms affect the susceptibility to hypertension.
What this study adds Although individual VEGF polymorphisms are not associated with hypertension, VEGF haplotypes (combinations of genetic variants) affect the susceptibility to hypertension, but not to resistant hypertension. The specific VEGF haplotype associated with protection against hypertension was more commonly found in subjects with higher concentrations of markers of nitric oxide formation.
